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Objective: Autoantibody and inflammatory cytokines play crucial roles in the develop-
ment of systemic lupus erythematosus (SLE); however, the regulation of their production 
warrants further investigation. This study aimed to investigate the role of basophil activa-
tion in the development of SLE based on studies in patients with SLE and spontaneous 
lupus-prone MRL-lpr/lpr mice.
Methods: The phenotypes of peripheral basophils and the production of autoantibody 
and interleukin (IL)-17 in patients with SLE were determined by flow cytometry and 
enzyme-linked immunosorbent assay, and also their correlations were investigated by 
statistical analysis. Thereafter, the effect of basophils on autoantibody production by 
B cells and Th17 differentiation in SLE were evaluated in vitro. Finally, the effect of baso-
phil depletion on the development of autoimmune disorders in spontaneous lupus-prone 
MRL-lpr/lpr mice was examined.
results: The decreased numbers and an increased activation of peripheral basophils 
were found to be correlated with increased autoantibody production and disease activity 
in patients with SLE. Correspondingly, in vitro coculture studies showed that basophils 
obtained from patients with SLE promoted autoantibody production by SLE B cells and 
promoted Th17 differentiation from SLE naïve CD4+ T cells. The decrease of periph-
eral basophils in patients with SLE might be due to their migration to lymph nodes 
post their activation mediated by (autoreactive) IgE as supported by their increased 
CD62L and CCR7 expressions and accumulation in the lymph nodes of MRL-lpr/lpr 
mice. Furthermore, an increased activation of peripheral basophils was identified in 
MRL-lpr/lpr mice. Importantly, basophil-depleted MRL-lpr/lpr mice exhibited an extended 
life span, improved renal function, and lower serum levels of autoantibodies and IL-17, 
while basophil-adoptive-transferred mice exhibited the opposite results.
conclusion: These finding suggest that basophil activation-dependent autoantibody 
and IL-17 production may constitute a critical pathogenic mechanism in SLE.
Keywords: basophil, ige, systemic lupus erythematosus, autoantibody, interleukin-17
TaBle 1 | Demographic characteristics of sle patients.
Total sle patients 
(n = 126)
newly diagnosed sle patients (n = 48) Followed-up sle patients (n = 15)
Age (mean ± SD) 28.7 ± 11.3 24.3 ± 10.5 25.9 ± 10.1
Gender [F/M, no. (%)] 107 (84.9%)/19 (15.1%) 45 (93.8%)/3 (6.2%) 14 (93.3%)/1 (0.7%)
Disease duration (mean ± SD, years) 4.7 ± 3.2
Anti-dsDNA IgG positive: no. (%) 94 (74.6%) 43 (89.6%) 14 (93.3%)
SLEDAI score
Mean ± SD 12.2 ± 7.0 17.2 ± 5.2 18.0 ± 5.5
Median (minimum, maximum) 12 (0, 30) 16 (11, 30) 19 (11, 27)
Treatment Treatment n (%) Patients no. + treatment
P 67 (53.2) 1. P + CTX 2. P + MMF
HCQ 32 (25.4) 3. P + AZA + TW 4. P + TW
MMF 4 (3.2) 5. P 6. P + CTX + TW
CTX 61 (48.4) 7. P + CTX 8. P + CTX + HCQ
AZA 7 (5.6) 9. P + CTX + TW 10. P + CTX
TW 54 (42.9) 11. P + CTX 12. P + HCQ
13. P + MMF 14. P + HCQ
15. P + MMF
SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; P, prednisone; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; CTX, cyclophosphamide; AZA, 
azathioprine; TW, Tripterygium wilfordi.
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inTrODUcTiOn
Systemic lupus erythematosus (SLE) is a systemic autoimmune 
disease that is characterized by the production of a wide spectrum 
of autoantibodies and inflammatory cytokines. Several types of 
immune cells are considered critical players in the induction of 
autoantibodies and inflammatory cytokine production in the 
pathogenesis of SLE, including overactivated B  cells, abnor-
mally activated T  cell subsets, monocytes, and dendritic cells 
(1–3). Of these cell types, overactivated B  cells play a central 
role by directly producing a large quantity of autoantibodies 
that can lead to systemic inflammation and organ damage 
(1, 4). However, the regulation of B  cell autoantibody produc-
tion is complex, and a variety of factors, such as other immune 
cells, environmental triggers, and genetic susceptibility, are 
involved (1, 5). For abnormally activated T cell subsets, increas-
ing evidence suggests that Th17 cells play a pivotal deleterious 
role in the inflammation and organ damage that occur in SLE 
(6, 7); thus, the regulation of Th17 differentiation in SLE warrants 
further investigation.
T  cell-dependent B  cell activation has been well character-
ized; however, T cell-independent B cell activation is not fully 
understood, particularly in autoimmune diseases (8). Basophils, 
one of the least abundant populations of granulocytes, are well 
known to be involved in allergic responses and also play criti-
cal roles in acquired immunity regulation and immunological 
disorders by releasing different patterns of immune modulators 
such as cytokines and chemokines upon activation by different 
stimuli (9, 10). It has been confirmed that basophils can deliver 
helper signals to B cells and drive their differentiation toward 
antibody-producing cells (11); however, the influence of baso-
phils on autoantibody production by B  cells in SLE is largely 
unknown.
Moreover, whether basophils promote the differentiation 
of Th17  cells remains controversial (12–15). Differences in the 
microenvironment and stimulatory conditions could be possible 
reasons for previous discrepant results. Th17 cells’ development 
requires synergistic effects mediated by series of cytokines, such 
as interleukin (IL)-23, IL-1β, TGF-β, and another key cytokine, 
IL-6, to drive their differentiation (16, 17). It is well documented 
that murine basophils can express IL-6 under specific conditions 
(18–20), but the effects of basophils on Th17 differentiation 
remain largely unknown in the context of SLE.
In 1990s, Hibbs et al. established a Src-family protein tyrosine 
kinase Lyn-deficient mouse model, which develops strong, con-
stitutive Th2 skewing in early life and exhibits symptoms of an 
autoimmune disease that mimics some of the features of human 
SLE in later life (21). Although this model is unlikely to model SLE 
in the majority of affected persons (22), basophils were shown to 
be indispensable for the development of autoimmune disease in 
these Lyn-deficient mice (23), which have provided the possible 
pathogenesis of basophils in SLE. However, the mechanistic links 
between basophils activation and SLE, especially its activation on 
autoantibody and inflammatory cytokines production in SLE, 
remain to be further elucidated.
This study aimed to investigate the role of basophil activation 
in the development of SLE based on studies in patients with SLE 
and spontaneous lupus-prone MRL-lpr/lpr mice, with a special 
focus on the effect of basophil activation on autoantibodies and 
inflammatory cytokine production in SLE.
MaTerials anD MeThODs
Patients
A total of 126 patients with SLE (107 females and 19 males) 
(Table  1) and 48 healthy controls (36 females and 12 males) 
with no differences with regard to age, sex, or race were enrolled 
into the present study at the Department of Nephrology at the 
Affiliated Hospital of Guangdong Medical University from 
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October 2012 to October 2015. Forty-eight newly diagnosed 
patients with active SLE without treatment (here termed newly 
diagnosed SLE) (Table 1) from the 126 patients with SLE enrolled 
were the main cohort studied. Fifteen patients (Table  1) were 
followed up during a 3-month period of treatment. All patients 
fulfilled the SLE classification criteria of the American College of 
Rheumatology (Atlanta, GA, USA) (24). The disease activity of 
the patients with SLE was evaluated using the SLE disease activity 
index (SLEDAI) (25). Exclusion criteria were as follows: patients 
with coinfections, allergies, other serious systemic diseases, and 
other autoimmune disorders.
This study was approved by the Ethics Committee of the 
Affiliated Hospital of Guangdong Medical University, and written 
informed consent was received from each subject.
Mice
Female MRL-lpr/lpr mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA) and maintained in the 
pathogen-free facility of the Laboratory Animal Center of 
Southern Hospital with the approval of the Ethics Committee for 
Experimental Animals at Nanfang Hospital, Southern Medical 
University. All experiments were performed according to the 
national guidelines for animal welfare.
Flow cytometric analysis
Human basophils were gated on FcεRIα-FITC/CD123-PerCP/
Cy5.5/CD203c-PE (BioLegend, San Diego, CA, USA) positive 
cells after extracellular and intracellular staining. The expression 
levels of CD203c-PE, CD62L-APC, FcεRIα-FITC, CCR7-APC, 
CD63-APC, IL-13-APC, B  cell-activating factor (BAFF)-APC 
(BioLegend, San Diego, CA, USA), IL-4-PE-Cy7, and IL-6-APC 
(eBioscience, San Diego, CA, USA) in basophils were quantified 
and expressed as relative fluorescence units (the ratio of mean 
fluorescence intensity normalized to controls) or as a positive 
percentage of total basophils.
Mouse basophils were gated on CD49b-APC/IgE-PE 
(BioLegend, San Diego, CA, USA). The expression levels of 
the activation marker CD200R-FITC (BioLegend, San Diego, 
CA, USA) (26), IL-4-FITC, and IL-6-FITC (eBioscience, San 
Diego, CA, USA) were quantified and expressed in the same 
way as for human basophils. A FACScanto™ Π flow cytometer 
(Becton Dickinson, San Jose, CA, USA) and Lysys II software 
(Becton Dickinson, San Jose, CA, USA) or FlowJo Software (Tree 
Star, San Carlos, CA, USA) were used to acquire and analyze the 
data.
Basophil Depletion or adoptive Transfer in 
Mrl-lpr/lpr Mice
Depletion of basophils in female MRL-lpr/lpr mice was performed 
by injection of 5  µg anti-mouse FcεRI (MAR1; eBioscience, 
San Diego, CA, USA) twice daily intraperitoneally for 3  days 
(18, 27), and control group (non-depleted) mice were treated 
with an isotype control antibody (eBioscience, San Diego, CA, 
USA). For basophil-adoptive-transfer, basophils were isolated 
from the peripheral blood of age-matched MRL-lpr/lpr mice 
using magnetic microbeads against CD49b+ (Miltenyi Biotec 
GmbH, Germany), and FcεRI+ and FcεRI++ basophils were 
further isolated by FACS-sorting (Becton Dickinson, San Jose, 
CA, USA) (27) to yield a purity of greater than 90%. Then, 1 × 104 
basophils per mouse were adoptively transferred through the tail 
vein. The cumulative survival to 36 weeks was monitored. Blood 
was obtained by puncture of the orbital venous plexus, and 
serum, urine, lymph nodes, and renal samples were collected at 
the indicated time points.
serum and Urine analysis
Serum levels of IL-17 in humans and IL-17 and INF-γ in 
mice were measured using enzyme-linked immunosorbent 
assay (ELISA) kits (Life Technologies, Grand Island, New 
York, NY, USA). Serum levels of antinuclear IgG in humans 
(Zeus Scientific, Inc., Branchburg, NJ, USA) or mice (Cusabio 
Biotech, Wuhan, China) were measured using ELISA kits. To 
test for anti-dsDNA IgE in human or antinuclear IgE in mice, an 
anti-dsDNA IgG ELISA kit (Fuchun Kexin Biotech, Shanghai, 
China) or an antinuclear IgG ELISA kit (Cusabio Biotech, 
Wuhan, China) was modified by using HRP-anti-human IgE or 
HRP-anti-mouse IgE as the secondary antibody, respectively, 
and the serum samples were diluted at 1:25. The results are 
expressed as standard units (international units per millilit-
ers, units per milliliters, or microgram per milliliters) or as 
the absorbance measured at 450 nm following a chromogenic 
(TMB) reaction (BioLegend, San Diego, CA, USA). Human 
serum IgE levels were determined using a chemiluminescence 
immunoassay (Elecsys 2010 analyzer, Roche Diagnostics Ltd., 
Switzerland).
To test for antinuclear IgE in humans, a line-blot method using 
the ANA Euroline Profile 3 kit (Euroimmun, Lübeck, Germany) 
was modified by using AP-anti-human IgE (Thermo Fisher 
Scientific, San Jose, CA, USA) as the secondary antibody, and the 
serum samples were diluted at 1:10.
For western blot detection of circulating immune complexes 
(CICs) containing IgE (IgE-CIC), PEG6000 (Sigma-Aldrich, St. 
Louis, MO, USA) (3.75%)-precipitated circulating CICs were pre-
pared (28); then, HRP-anti-human IgE (Abcam Inc., Cambridge, 
MA, USA) was used for detection.
Twenty-four-hour urine was collected from metabolic 
cages to determine the levels of serum creatinine, C3 (Alpha 
Diagnostic Intl. Inc., San Antonio, TX, USA), blood urea nitrogen 
(StressMarq Biosciences Inc., Victoria, BC, Canada), and urinary 
proteins (Bradford method, Bio-Rad protein assay reagent).
Tissue analysis
Immunofluorescence analysis was conducted to measure 
immunoglobulin deposition in human and mouse kidneys (29). 
FITC anti-human IgG (Sigma-Aldrich, St. Louis, MO, USA) and 
human IgE (eBioscience, San Diego, CA, USA), as well as FITC 
anti-mouse IgG (Santa Cruz Biotechnology, CA, USA) and IgE 
(eBioscience, San Diego, CA, USA) were employed. For human 
biopsy, the fluorescence intensity of glomerular staining was 
graded on a scale from 0 to ++++ in increments of 0.5+. Images 
were recorded under a TCS SP5 II confocal microscope (Leica 
Microsystems, Mannheim, Germany).
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isolation and activation assays of human 
Basophils
An EasySep™ human basophil enrichment kit (Stemcell 
Technologies, Vancouver, BC, Canada) was used to negatively 
purify human basophils to obtain a purity of greater than 90% 
using flow cytometry (30).
For activation analysis, human basophils isolated from healthy 
controls were aliquoted at 4,000  cells/well in a total volume of 
200 µl medium containing IL-3 (2 ng/ml, PeproTech., London, 
UK); to these were added the AB serum of healthy controls (20% 
of a total volume) or newly diagnosed patients with SLE (20% 
of a total volume), or CICs that were precipitated by PEG 6000 
(3.75%) from the serum of newly diagnosed patients with SLE 
(31), or serum from newly diagnosed SLE patients that flow 
through a Sepharose 4B™ column (GE Healthcare, Uppsala, 
Sweden) coupled with anti-IgE antibody to depletion of IgE (32), 
or anti-IgE antibody (0.5 µg/ml; positive control) (Abcam Inc., 
Cambridge, MA, USA) at 37°C for 15 min (CD203c detection) or 
24 h (CD62L, CCR7, and IL-4-positive detection) (33).
autoantibody Production assay
B  cells were isolated from newly diagnosed patients with SLE 
using an EasySep™ Human B Cell Enrichment kit (Stemcell 
Technologies, Vancouver, BC, Canada) (34). Then, for the meas-
urement of autoantibody production, B cells (1 × 105 cells/well) 
were cultured for 12 days with polyclonally activated CD4+ T cells 
(1 × 105 cells/well) from healthy controls using anti-CD3 (0.5 mg/
ml) (Miltenyi Biotec GmbH, Germany); or negatively purified 
basophils (5 × 104 cells/well) from healthy control or newly diag-
nosed patients with SLE. Cells were cultured in DMEM (300 µl) 
(10% FBS), IL-2 (10  ng/ml) and IL-3 (10  ng/ml) (PeproTech) 
(18, 35), as well as nuclear extracts of Hep-2 cells (10  µg/ml) 
isolated with a Nuclear and Cytoplasmic Extraction Kit (Thermo 
Fisher) as a stimulator for the first 3 days (36). Levels of antinu-
clear IgG (Zeus Scientific) and IgE (as described in serum and 
urine analysis, and culture supernatant samples were diluted 1:4), 
anti-nucleosomes IgG (ELISA) (Euroimmun, Lübeck, Germany) 
and IgE, and anti-tetanus IgG (ELISA) (ZhengZhou Etebio 
Technology Co., Ltd., Zhengzhou, China, approved by SFDA) 
and IgE in the culture supernatants were measured using ELISA 
kits.
Th17 Differentiation assay
Naïve CD4+ T  cells from newly diagnosed patients with SLE 
using an EasySep™ Human Naïve CD4+ T Cell Enrichment 
Kit (Stemcell technologies) were stimulated with anti-CD2/
CD3/CD28 T cell activation beads (Miltenyi Biotec) at a bead-
to-cell ratio of 1:2 for 3 days, followed by incubation for 4 days 
in the presence of a Th17 differentiation cytokine mixture (IL-2, 
20 ng/ml; IL-6, 20 ng/ml; IL-23, 20 ng/ml; IL-1β, 20 ng/ml; TGF-
β1, 5 ng/ml; anti-IL-4, 5 µg/ml; anti-IL-12, 5 µg/ml; anti-IFN-γ. 
1  µg/ml; PeproTech., London, UK), or culturing in the Th17 
differentiation cytokine mixture (excluding IL-6) with negatively 
isolated basophils (2 × 104 cells/well) from healthy controls, or 
from newly diagnosed patients with SLE in the absence or pres-
ence of anti-IL-6 (5 µg/ml, PeproTech., London, UK), respectively.
statistics
All statistical analysis was performed using SPSS 16.0 (SPSS, Inc., 
Chicago, IL, USA). Two-group comparisons were performed 
using unpaired two-tailed Student’s t-test. Multiple-group 
comparisons were performed using one-way analysis of vari-
ance (ANOVA) followed by the Bonferroni or Dunnett post hoc 
tests. Survival curves were analyzed using the non-parametric 
Kaplan–Meier method. Spearman’s rank correlation was used to 
detect correlations among different study parameters. A P-value 
of <0.05 was considered to indicate statistical significance. Each 
symbol represents an individual patient, one mouse, or one 
sample. The data are presented as scatter plots and are expressed 
as means.
resUlTs
Decreased numbers and increased 
activity of Peripheral Basophils are 
correlated with Disease activity and 
increased autoantibody Production in 
Patients with sle
To assess whether basophils play a role in SLE, the numbers 
and activation of peripheral basophils and their correlations 
with disease activity (SLEDAI score) were evaluated in patients 
with SLE. The results showed that the number (Figure 1A—a) 
and percentage (Figure  1A—b) of peripheral basophils in 
newly diagnosed patients with SLE were significantly decreased 
compared with healthy controls. However, these basophils were 
activated and exhibited higher expression levels of activation 
makers such as CD203c and CD63 (Figure  1A—c and d) 
compared with those from healthy controls. The representative 
data of FACS for basophil frequency, CD203c, and CD63+ were 
also shown (Figure S1 in Supplementary Material) The higher 
expression of CD203c on basophils correlated with disease 
activity, as assessed by the SLEDAI score, not only in the newly 
diagnosed SLE patients (Figure  1B—a) but also in the total 
group of patients with SLE (Figure  1B—b). Additionally, the 
higher expression of CD203c on basophils correlated with the 
serum levels of antinuclear IgG and IgE (Figure 1B—c and d) 
along with the deposition of IgG and IgE in kidney biopsies 
(Figure 1C) in the total group of patients with SLE. Furthermore, 
a follow-up study showed that after treatment with immuno-
suppressants and other drugs, newly diagnosed patients with 
SLE who experienced effective treatment (defined as a decrease 
in the SLEDAI score of more than 6 and the absence of damage 
to the heart, lungs, brain, blood, intestines, or any other vital 
organs) showed an increased level of peripheral basophils and 
decreased basophil activity as indicated by the expression of 
CD203c (Figure 1D, nos.1–13); in contrast, patients who did 
not experience effective treatment did not show any of these 
signs (Figure  1D, nos.14 and 15). Also, patients with SLE 
who treated with Tripterygium wilfordi have been shown apart 
(Figure S2 in Supplementary Material). These findings indicate 
that peripheral basophil activation may play an important role 
in SLE.
FigUre 1 | numbers and activation of peripheral basophils and their correlations with disease activity and autoantibody production in patients with 
systemic lupus erythematosus (sle). (a) The number (a, b) and activation (CD203c expression and CD63 positive percentage) (c, d) of peripheral basophils in 
newly diagnosed patients with SLE (n = 48) and healthy controls (n = 48) were detected using flow cytometry. (B) Correlations between the activation (CD203c 
expression) of peripheral basophils and disease activity [SLE disease activity index (SLEDAI) score] of newly diagnosed patients with SLE (n = 48) (a), or total 
patients with SLE (n = 126) (b), levels of their serum antinuclear IgG (n = 126) (c), and IgE (n = 126) (d) were analyzed. (c) The association between the activation 
(CD203c expression) of peripheral basophils in patients with SLE (n = 97) who received renal biopsy and the deposition of IgG (a) and IgE (b) evaluated by 
fluorescence intensity grade in biopsied kidneys. (D) Changes in the SLEDAI score (a), the numbers (b), and activation (CD203c expression) (c) of peripheral 
basophils in patients with SLE (n = 15) who were followed up for 3 months posttreatment. *P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed via Student’s 
t-test (a,D), Spearman’s rank correlation (B), or one-way analysis of variance (c) and presented as scatter plots and are expressed as means.
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(autoreactive) ige-Mediated Basophil 
activation in Patients with sle
Since peripheral basophils in patients with SLE were in an 
activated state, we next examined the mechanisms mediating 
their activation by looking into the potential involvement of 
IgE, a key inducer of basophil activation. The results showed 
that serum levels of anti-dsDNA IgE, antinuclear IgE and 
total IgE (Figure  2A), IgE-CIC (Figure  2D) in newly diag-
nosed patients with SLE were significantly higher than those 
in healthy controls, which was reconfirmed by the higher 
expression of the high-affinity receptor for IgE (FcεRIα) on 
basophils (Figure 2B). In addition, antinuclear IgE specific for 
auto-antigens, including nRNP/sm, Sm, SS-A, Ro-52, dsDNA, 
nucleosomes, rib-Prot, etc., can be detected in patients with 
SLE (n = 36) but not in healthy controls (n = 36) (Figure 2C). 
In an in  vitro study, we found that peripheral basophils that 
were negatively isolated from healthy controls (Figure  2E) 
could be activated by the upregulation of CD203c expression 
(Figure  2F—a) and that the percentage of IL-4-positive cells 
(Figure  2F—b) could be increased by culturing with serum 
obtained from newly diagnosed patients with SLE, and IgE-
CICs (Figure 2D) precipitated by PEG from the sera of newly 
diagnosed patients with SLE, but not by the serum of healthy 
controls or serum obtained from newly diagnosed patients with 
SLE by depletion of IgE. Basophils were activated with anti-IgE 
stimulation as a positive control (Figure  2F). These findings 
indicate that the presence of IgE, especially autoreactive IgE, 
mediate basophil activation in SLE.
Basophils Promote autoantibody 
Production by B cells and Th17 
Differentiation in sle
To clarify the triggers that decrease basophil counts in patients 
with SLE, we investigated the homing of basophils to the lymph 
nodes and the mechanisms that mediate this process. Our 
results showed that CD62L and CCR7, which are important 
for the homing of T  cells to lymphoid tissues (37, 38), were 
upregulated on basophils obtained from newly diagnosed 
patients with SLE compared with those obtained from healthy 
controls (Figure  3A). Additionally, the expression levels of 
CD62L and CCR7 (Figure  3B) on peripheral basophils that 
were negatively isolated from healthy controls were increased 
by culturing with serum obtained from newly diagnosed 
patients with SLE but not by culturing with serum obtained 
from healthy controls.
We then examined the role of activated basophils from 
patients with SLE in autoantibody production by B  cells from 
patients with SLE in vitro. The results showed that the percentages 
of IL-4-, IL-6-, IL-13-, and BAFF-positive peripheral basophils 
in newly diagnosed patients with SLE were significantly higher 
than those in healthy controls (Figure 3C). Moreover, basophils 
obtained from patients with SLE promoted antinuclear IgG 
and IgE production by B cells obtained from patients with SLE 
in vitro, but not those from healthy controls (Figure 3D—a and 
b). Also, anti-nucleosome IgG and IgE production has the same 
tendency (Figure 3D—c and d), while anti-tetanus IgG and IgE 
were not detected (data not shown). The coculture of activated 
T cells with B cells obtained from patients with SLE was used to 
produce autoantibodies as a positive control (Figure 3D). These 
findings demonstrate that basophils can amplify autoantibody 
production by B cells in SLE.
Next, we investigated the role of activated basophils from 
patients with SLE on Th17 differentiation from naïve CD4+ 
T  cells from patients with SLE in  vitro. Similar to what was 
observed with B cells, the results showed that isolated basophils 
from newly diagnosed patients with SLE significantly promoted 
Th17 differentiation compared to those obtained from healthy 
controls in the presence of a cytokine mixture (excluding IL-6) 
to induce Th17 differentiation (Figure  3E—a and b), and this 
effect could be suppressed by adding anti-IL-6 antibodies 
(Figure  3E—b), which was consistent with the finding that 
newly diagnosed patients with SLE had a higher percentage of 
IL-6-positive peripheral basophils (Figure  3C—b) and higher 
serum IL-17 levels (Figure 3E—c) than healthy controls. These 
findings demonstrate that basophils can promote Th17 differen-
tiation in SLE.
activated Basophils exacerbate Disease 
Progression in Mrl-lpr/lpr Mice
Because clinical data and in vitro studies have indicated that acti-
vated basophils can promote autoantibody and IL-17 production 
and may exacerbate SLE, a lupus-prone MRL-lpr/lpr mice model 
that reflects the pathologies of human SLE (39) was employed to 
further investigate the role of basophils in SLE.
Compared to those in 6-week-old MRL-lpr/lpr mice, the 
expression levels of basophil activation markers, including 
CD200R (26), IL-4, and IL-6, were upregulated in 10- and 
14-week-old mice (Figure 4A). Additionally, basophils were first 
detected in the lymph nodes of 10-week-old MRL-lpr/lpr mice 
and increased slightly in number as the mice aged (Figure 4D), a 
finding that is consistent with the upregulated expression of the 
homing receptors CD62L and CCR7 on basophils obtained from 
patients with SLE (Figure 3A).
We next evaluated the effects of basophil depletion and 
adoptive transfer on the development of autoimmune disorders 
in MRL-lpr/lpr mice. The experimental design and timelines 
was shown in Figure 4B. The results showed that one time of 
basophil depletion led to a significant decrease in the percent-
age of basophils in the peripheral blood (Figure  4C), lymph 
nodes (Figure 4D), and spleen (data not shown) of MRL-lpr/lpr 
mice and that this decrease lasted for more than 10 days. When 
basophils were depleted five times from 6 to 14 weeks of age, the 
survival of MRL-lpr/lpr mice was significantly prolonged com-
pared with that of control and basophil-adoptive-transferred 
mice (Figure 4E).
In addition, basophil-depleted MRL-lpr/lpr mice exhibited a 
significant decrease in the ratio of spleen weight to body weight 
(Figure  4F) and the levels of serum antinuclear IgG and IgE 
at 20  weeks (Figure  5A), and an increase in the serum levels 
of C3 (Figure 5C) at 15 and 20 weeks compared with controls 
and basophil-adoptive-transferred mice. Basophil-depleted 
MRL-lpr/lpr mice exhibited significant decreases in the levels of 
FigUre 2 | Mechanism of peripheral basophil activation in patients with systemic lupus erythematosus (sle). (a) Serum levels of anti-dsDNA IgE, 
antinuclear IgE, and total IgE (n = 48); (B) levels of FcɛRIα expression on peripheral basophils (n = 48); (c) antinuclear IgE profile (n = 36) (shown as representative 
images); and (D) the relative ratio of IgE-circulating immune complexes (CICs) (n = 15) in newly diagnosed patients with SLE and the same number of healthy 
controls. (e) Representative FCM dot-plot of peripheral basophils in PBMC of healthy controls (n = 6) (a) and post negatively isolated (b). (F) Activation [CD203c 
expression and interleukin (IL)-4 positive percentage] of basophils from healthy controls (n = 8) after stimulation with serum (20% of a total volume) of healthy control 
or newly diagnosed patients with SLE, CICs of newly diagnosed patients with SLE, serum (20% of a total volume) of newly diagnosed patients with SLE by depletion 
of IgE, or anti-IgE. *P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed via Student’s t-test (a,B,D) or one-way analysis of variance (F) and presented as scatter 
plots and are expressed as means.
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FigUre 3 | continued
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FigUre 3 | analysis of homing receptors expression on basophils and the effect of basophils on autoantibody production by B cells and Th17 
differentiation in systemic lupus erythematosus (sle). The expression of homing receptors (CD62L and CCR7) on (a) peripheral basophils of healthy controls 
(n = 48) and newly diagnosed patients with SLE (n = 48) and (B) basophils from healthy controls after stimulation with serum (20% of a total volume) of healthy 
control (n = 8) and newly diagnosed patients with SLE (n = 8) for 24 h. (c) The percentages of interleukin (IL)-4− (a), IL-6− (b), IL-13− (c), and BAFF-positive (d) 
peripheral basophils in newly diagnosed patients with SLE and healthy controls (n = 48). (D) Antinuclear IgG (a), antinuclear IgE (b), anti-nucleosome IgG (c), and 
anti-nucleosome IgE (d) produced by SLE B cells post-coculturing with basophils from healthy controls or newly diagnosed patients with SLE and activated T cells 
for 12 days (n = 6). (e) The proportions of Th17 differentiation from SLE naïve CD4+ T cells post-coculturing in Th17 differentiation cytokines mixture (IL-6 included), 
or post-coculturing in Th17 differentiation cytokine mixture (excluding IL-6) with basophils from healthy controls (a, left, representative FCM plots), or basophils from 
newly diagnosed patients with SLE (a, right) in the absence or presence of anti-IL-6, respectively, and the statistical data (n = 9) (b), and serum levels of IL-17 in 
newly diagnosed patients with SLE (n = 48) and healthy controls (n = 48) (c). *P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed via Student’s t-test (a–c—e) 
or one-way analysis of variance (D,e—b) and presented as scatter plots and are expressed as means.
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FigUre 4 | continued
FigUre 4 | effect of basophil depletion or adoptive transfer on the survival of Mrl-lpr/lpr mice. (a) CD200R expression (a) on peripheral basophils and 
the percentages of interleukin (IL)-4− (b) and IL-6-positive (c) peripheral basophils in MRL-lpr/lpr mice (n = 6). (B) Experimental design and time lines. (c) The 
changes of percentages of peripheral basophils to leukocytes in MRL-lpr/lpr mice (n = 6) after basophil depletion. (D) The changes of percentages of basophils to 
lymphocytes in the lymph nodes of control, basophil–depleted, and basophil-adoptive-transferred MRL-lpr/lpr mice (n = 6) (a) and statistical data (b). (e) The 
cumulative survival of three groups of MRL-lpr/lpr mice (n = 12) was monitored using the Kaplan–Meier method. (F) Representative images of the spleens of control, 
basophil–depleted, and basophil-adoptive-transferred MRL-lpr/lpr mice (from left to right) (a) and statistical data of the percentage of spleen weight to body weight 
of them (b) (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed via one-way analysis of variance (a,D,F) and Student’s t-test (c) and presented as 
scatter plots and are expressed as means.
10
Pan et al. Activated Basophil Exacerbate SLE
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 348
serum IL-17, but not IFN-γ, at 20 weeks compared with control 
and basophil-adoptive-transferred mice (Figure 5B).
The influence of basophil depletion on renal injury in 
MRL-lpr/lpr mice was also assessed. Serum levels of creatinine, 
blood urea nitrogen, and urinary proteins were significantly 
decreased in basophil-depleted MRL-lpr/lpr mice at 20 weeks of 
age (Figure 5D). Basophil-depleted MRL-lpr/lpr mice exhibited 
decreased levels of IgG and IgE deposition in the glomeruli com-
pared with the control and basophil-adoptive-transferred mice 
(Figure 5E—a). Additionally, the renal histopathology (including 
enlarged glomeruli, glomerular cell proliferation, and increased 
mesangial matrix) of basophil-depleted MRL-lpr/lpr mice 
was improved at 20  weeks compared with that of the controls 
(Figure 5E—b); however, basophil (from age-matched-MRL-lpr/
lpr mice) adoptive-transferred MRL-lpr/lpr mice showed more 
severe glomerulonephritis than the controls (Figure 5E).
DiscUssiOn
In this study, we used negatively isolated human basophils together 
with patient information and a lupus-prone mouse model to 
demonstrate that activated basophils amplify autoantibody 
and IL-17 production, thereby contributing to the pathogenesis 
of SLE.
Because basophils need to be activated to fulfill their biological 
functions (40, 41), we first demonstrated that basophils obtained 
from patients with SLE and MRL-lpr/lpr mice were activated due 
to higher expression of a series of activation markers and that 
FigUre 5 | effects of basophil depletion or adoptive transfer on autoantibodies and inflammatory cytokines production and renal pathology of 
Mrl-lpr/lpr mice. Serum levels of antinuclear IgG and IgE (a), interleukin (IL)-17 and IFN-γ (B), C3 (c), and (D) serum creatinine (a), blood urea nitrogen (b), and 
urinary proteins (c) in control, basophil–depleted, and basophil-adoptive-transferred MRL-lpr/lpr mice (n = 6). (e) Representative images of the fluorescence 
microscopy examination of IgG and IgE deposition (e—a); and the light microscopy examination of the histopathology of glomerulonephritis using H&E and PAS 
staining (e—b) in control, basophil–depleted, and basophil-adoptive-transferred MRL-lpr/lpr mice (n = 6) at 20 weeks of age (scale bars, 50 µm). Ba, basophil. 
*P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed via one-way analysis of variance (a–D) and presented as scatter plots and are expressed as means.
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some of these also correlated with disease activity in SLE. Then, 
we found that IgE, especially autoreactive IgE, mediated basophil 
activation in SLE, based on the detection of abundant total IgE, 
autoreactive IgE, and the higher expression of the high-affinity 
receptor for IgE (FcεRIα) on basophils in patients with SLE, and 
in  vitro experiments including isolated basophils cocultured 
with the serum of patients with SLE and PEG precipitation CIC 
(containing IgE). The prevalence of autoreactive IgE in SLE was 
also observed by others (23, 42, 43).
In addition to activation, we simultaneously found that the 
numbers of peripheral basophils were decreased in patients 
with SLE. Thus, we evaluated where the basophils traf-
ficked to following their activation. We found that basophils 
were initially detected in the lymph nodes in 10-week-old 
MRL-lpr/lpr mice, and this number increased slightly as the mice 
aged, which confirmed the results of a previous study showing 
that basophils were detected in the lymph nodes and spleen in two 
patients with SLE (23). These findings demonstrate the homing of 
basophils to lymph nodes in SLE. A subsequent study indicated 
that basophil migration to lymphoid tissues might mediated by 
CD62L and CCR7, based on the higher expression of these two 
homing receptors on basophils in patients with SLE as well as an 
in  vitro experiment. Higher expression of CD62L by basophils 
of patients with SLE was also was also observed by others (23). 
Above all, homing to lymphoid tissues after basophil activation 
may contribute to decreased peripheral basophil numbers in SLE.
In this study, we mainly focused on the effects of activated 
basophils after homing to lymphoid tissues in SLE. The first key 
issue to clarify was the effect of activated basophils on autoan-
tibody production by B cells in SLE. It has been confirmed that 
basophils can directly interact with B  cells and provide helper 
signals to them through IL-4, IL-13, BAFF, and CD40L, driving 
their differentiation to antibody-producing cells (11). Our in vitro 
study showed that basophils from patients with SLE have the 
ability to promote autoantibodies including antinuclear and anti-
nucleosome IgG and IgE production by B cells. For the immu-
nological basis, this effect was possibly mediated by a synergistic 
effect of IL-4, IL-6, IL-13, and BAFF, together with the constitutive 
expression of CD40L (35, 44), as confirmed by our observation 
of a high expression level of these effectors by basophils of SLE 
patients (Figure 3C). This is consistent with the finding that baso-
phil activation was correlated with the serum levels of antinuclear 
antibodies and with the deposition of immunoglobulins in the 
glomeruli of patients with SLE. Correspondingly, our in vivo study 
also showed that basophil-depleted MRL-lpr/lpr mice exhibited 
markedly decreased levels of serum autoantibodies and immuno-
globulin deposition in glomeruli. However, anti-tetanus IgG/IgE 
in the culture supernatants was not detected (data not shown). For 
the next step, we plan to investigate which effectors play key roles 
in the synergistic effect of them in the context of SLE.
We next investigated another key issue: the effect of activated 
basophils on Th17 differentiation in SLE. Our in  vitro study 
first showed that activated basophils obtained from patients 
with SLE could promote Th17 differentiation. Furthermore, 
basophil-depleted MRL-lpr/lpr mice exhibited significant 
decreases in their serum IL-17 levels. The finding that activated 
basophils enhance IL-17 production has also been reported in 
another autoimmune disease, inflammatory bowel disease (12). 
Further analysis showed that IL-6, which is also defined as a 
Th17-inducing cytokine (20) due to its role in the regulation 
of Th17 differentiation (45), was necessary for promoting Th17 
differentiation and IL-17 production by activated basophils in 
patients with SLE, as further confirmed by our observation that 
basophils obtained from patients with SLE and aged MRL-lpr/lpr 
mice both exhibited a higher expression of IL-6.
Moreover, to directly verify the role of basophils in SLE pro-
gression, a selective basophil-depletion murine model was suc-
cessfully established, as reported previously (18, 46). Our results 
showed that basophils were activated along with aging, and the 
homing of basophils to lymph nodes was significantly inhibited 
after depletion of basophils in MRL-lpr/lpr mice. Consequently, 
the basophil-depleted mice exhibited benefits on renal function 
and attenuated the progression of glomerulonephritis, finally 
led to the extension of life span, which was accompanied with 
significant decreases in autoantibody and IL-17 production. 
However, basophil-adoptive-transferred MRL-lpr/lpr mice 
exhibited the opposite tendency, although the results were not 
significant possibly because the peripheral basophils were suf-
ficient for migration, which is consistent with the observation 
that basophils were not significantly increased in the lymph 
nodes of the basophil-adoptive-transferred mice. In addition, we 
also used the antibody anti-CD200R3 (Ba103; Hycult, Uden, The 
Netherlands) for basophil depletion (47), and the results showed 
the same tendency (data not shown). In another study, basophils 
were found to be necessary for the development of autoimmune 
disease in Lyn-deficient mice (23). We noted that due to the 
induction of antibodies to basophil-depletion antibodies, the 
prolonged use of them in vivo was limited, and also the efficiency 
of basophil depletion in MRL-lpr/lpr mice was decreased for the 
fifth basophil depletion compared with the first time even it can 
led to a significant decrease in the percentage of basophils in the 
peripheral blood lasted for more than 6 days. Recently, several 
kinds of basophil ablation mouse models, Tg mouse, have been 
generated (48, 49), which will help us to further study the critical 
roles of basophils in SLE in the future. These findings demon-
strate that activated basophils exacerbate disease progression in 
MRL-lpr/lpr mice.
cOnclUsiOn
This study demonstrates that basophils can exacerbate SLE 
through activation-dependent autoantibody and IL-17 produc-
tion (Figure  6). These findings provide novel insights into the 
pathogenesis of SLE and may lead to the development of new 
therapeutic strategies for treating SLE.
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FigUre 6 | schematic representation of systemic lupus erythematosus (sle) exacerbation by basophil activation-dependent autoantibody and 
interleukin (il)-17 production. During the progress of SLE, peripheral basophils could migrate to secondary lymphoid tissues in response to the increased 
expression of CD62L/CCR7 post their activation mediated by (autoreactive) IgE. At these sites, basophils could exacerbate SLE by promoting autoantibody 
production possibly mediated by a synergistic effect of IL-4, IL-6, IL-13, BAFF, and CD40L, and Th17 differentiation by IL-6 resulted in the exacerbating of disease.
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FigUre s1 | representative data of Facs for basophil frequency, 
cD203c, and cD63+ basophil. Gate 1 (①) isolates the peripheral leukocytes, 
and gate 2 (②) detects the low side-scatter (SSC), FcεRIα+ population of cells. 
Then, with a double gating strategy, gate 3 (③) detects CD123+CD203c+ basophil 
population. For CD63+ basophil, a followed gate 4 (④) detects the low SSC, 
FcεRIα+CD123+CD203c+CD63+ population of basophil. Gates were set 
according to isotype controls antibodies, respectively. The results were analyzed 
with FlowJo Software in a pseudocolor dot-plot.
FigUre s2 | numbers and activation of peripheral basophils and their 
correlations with disease activity and autoantibody production in 
patients with systemic lupus erythematosus (sle) treated with 
Tripterygium wilfordi. (a) Correlations between the activation (CD203c 
expression) of peripheral basophils and disease activity [SLE disease activity 
index (SLEDAI) score] (a), and levels of their serum antinuclear IgG (b) or IgE (c) of 
patients with SLE treated with T. wilfordi (n = 54) were analyzed. (B) Changes in 
the SLEDAI score (d), the numbers (e), and activation (CD203c expression) (f) of 
peripheral basophils in patients with SLE treated with T. wilfordi (n = 4) who were 
followed up for 3 months posttreatment. *P < 0.05, **P < 0.01, ***P < 0.001. 
Data were analyzed via Spearman’s rank correlation (a) or one-way analysis of 
variance (B) and presented as scatter plots and are expressed as means.
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